Figure 10From: Infliximab: 12 years of experiencePsoriatic arthritis: improvement of joint symptoms. Infliximab significantly improves joint symptoms compared with placebo (P <0.001 at week 16) in the IMPACT 1 study (n = 104 patients) [82]. (a) Prior to crossover. (b) Open-label extension, up to 54 weeks. ACR, American College of Radiology.Back to article page